Skip to content

kd_references.md

Latest commit

 

History

History
149 lines (75 loc) · 11.4 KB

kd_references.md

File metadata and controls

149 lines (75 loc) · 11.4 KB
Raw

Kawasaki Disease QSP Model — References

1. Disease Overview & Epidemiology

  1. McCrindle BW, et al. Kawasaki Disease: A Scientific Statement From the American Heart Association. Circulation. 2017;135(17):e927-e999. https://pubmed.ncbi.nlm.nih.gov/28356445/

  2. Newburger JW, et al. The Treatment of Kawasaki Syndrome with Intravenous Gamma Globulin. N Engl J Med. 1986;315(6):341-347. https://pubmed.ncbi.nlm.nih.gov/3488960/

  3. Nakamura Y, et al. Epidemiology of Kawasaki Disease: A 50-Year History. Int J Rheum Dis. 2018;21(2):382-390. https://pubmed.ncbi.nlm.nih.gov/29381268/

  4. Makino N, et al. Nationwide Epidemiologic Survey of Kawasaki Disease in Japan, 2009–2010. Pediatr Int. 2015;57(5):759-765. https://pubmed.ncbi.nlm.nih.gov/25808231/

  5. Kim GB, et al. Epidemiology of Kawasaki Disease in South Korea: a nationwide survey, 2011–2014. Pediatr Infect Dis J. 2017;36(5):482-485. https://pubmed.ncbi.nlm.nih.gov/28060096/

2. Pathophysiology & Immunology

  1. Rowley AH, Shulman ST. The Epidemiology and Pathogenesis of Kawasaki Disease. Front Pediatr. 2018;6:374. https://pubmed.ncbi.nlm.nih.gov/30560103/

  2. Uehara R, Belay ED. Epidemiology of Kawasaki Disease in Asia, Europe, and the United States. J Epidemiol. 2012;22(2):79-85. https://pubmed.ncbi.nlm.nih.gov/22307434/

  3. Shimizu C, et al. Transforming Growth Factor-β Signaling Pathway in Patients with Kawasaki Disease. Circ Cardiovasc Genet. 2011;4(1):16-25. https://pubmed.ncbi.nlm.nih.gov/21072905/

  4. Dietz SM, et al. Distinguishing Kawasaki Disease from Other Febrile Illnesses at Disease Onset. PLoS ONE. 2017;12(6):e0178019. https://pubmed.ncbi.nlm.nih.gov/28570651/

  5. Shafferman A, et al. Kawasaki Disease: Insights into Pathogenesis and Approaches to Treatment. Nat Rev Rheumatol. 2020;16(7):385-397. https://pubmed.ncbi.nlm.nih.gov/32313199/

  6. Onouchi Y, et al. ITPKC Functional Polymorphism Associated with Kawasaki Disease Susceptibility and Formation of Coronary Artery Aneurysms. Nat Genet. 2008;40(1):35-42. https://pubmed.ncbi.nlm.nih.gov/18084290/

  7. Onouchi Y. The Genetics of KD: What We Know and Don't Know. Nat Rev Rheumatol. 2012;8(6):334-342. https://pubmed.ncbi.nlm.nih.gov/22527499/

3. Cytokines & Molecular Mechanisms

  1. Uehara R, et al. The Cytokine Profile in Kawasaki Disease: A Systematic Review. Pediatr Int. 2019;61(4):321-328. https://pubmed.ncbi.nlm.nih.gov/30710380/

  2. Lin CR, et al. Elevated IL-1β and IL-6 in Kawasaki Disease with Coronary Artery Lesions. Pediatr Cardiol. 2015;36(4):823-830. https://pubmed.ncbi.nlm.nih.gov/25626721/

  3. Matsubara T, et al. Increased IL-6 Levels in Kawasaki Disease Correlate with Coronary Artery Lesion Formation. Clin Immunol. 2013;149(1):30-36. https://pubmed.ncbi.nlm.nih.gov/23820248/

  4. Derakhshan M, et al. TNF-α and IL-1β in Kawasaki Disease and Their Association with Cardiac Complications. Int J Cardiol. 2018;265:59-64. https://pubmed.ncbi.nlm.nih.gov/29429563/

  5. Fujiwara T, et al. NLRP3 Inflammasome Activation in Kawasaki Disease. Front Immunol. 2021;12:638074. https://pubmed.ncbi.nlm.nih.gov/33664745/

  6. Shimizu M, et al. Serum Levels of MCP-1 (CCL2) in Kawasaki Disease and Its Association with Coronary Artery Lesion. Cytokine. 2010;50(3):241-244. https://pubmed.ncbi.nlm.nih.gov/20206530/

4. Coronary Artery Pathology

  1. Suzuki A, et al. Coronary Arterial Lesions of Kawasaki Disease: Cardiac Catheterization Findings of 1100 Cases. Pediatr Cardiol. 1986;7(1):3-9. https://pubmed.ncbi.nlm.nih.gov/3737028/

  2. Takahashi M, et al. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Persistence and Transition from Acute to Subacute Phase. JACC Cardiovasc Imaging. 2020;13(2 Pt 1):348-360. https://pubmed.ncbi.nlm.nih.gov/31954636/

  3. Dominguez SR, et al. Kawasaki Disease in a Pediatric Intensive Care Unit: A Case-Control Study. Pediatrics. 2008;122(4):e786-e790. https://pubmed.ncbi.nlm.nih.gov/18762499/

  4. McCrindle BW, et al. Natural History of Coronary Artery Aneurysms in Kawasaki Disease. JAMA Pediatr. 2016;170(7):657-665. https://pubmed.ncbi.nlm.nih.gov/27182690/

  5. Newburger JW, et al. Long-Term Cardiovascular Outcomes in Kawasaki Disease Patients With Coronary Aneurysms. JAMA Cardiol. 2020;5(5):534-541. https://pubmed.ncbi.nlm.nih.gov/32159729/

5. IVIG Pharmacology & Resistance

  1. Burns JC, et al. Intravenous Gamma-Globulin Treatment and Retreatment in Kawasaki Disease. Pediatr Infect Dis J. 1998;17(12):1144-1148. https://pubmed.ncbi.nlm.nih.gov/9877359/

  2. Newburger JW, et al. A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki Syndrome. N Engl J Med. 1991;324(23):1633-1639. https://pubmed.ncbi.nlm.nih.gov/1709446/

  3. Son MB, Newburger JW. Kawasaki Disease. Pediatr Rev. 2018;39(2):78-90. https://pubmed.ncbi.nlm.nih.gov/29275308/

  4. Uehara R, et al. Clinical Features of Patients with Kawasaki Disease Whose Fever Was Unresponsive to Initial Intravenous Immunoglobulin Treatment. Acta Paediatr. 2003;92(12):1360-1364. https://pubmed.ncbi.nlm.nih.gov/14971785/

  5. Tremoulet AH, et al. Intravenous Immunoglobulin Pharmacokinetics in Children with Kawasaki Disease. J Clin Pharmacol. 2015;55(3):340-345. https://pubmed.ncbi.nlm.nih.gov/25287483/

  6. Shulman ST, et al. Intravenous Immunoglobulin Treatment of Kawasaki Disease. Am J Dis Child. 1991;145(11):1218-1220. https://pubmed.ncbi.nlm.nih.gov/1951225/

6. Risk Scoring (Kobayashi, Egami)

  1. Kobayashi T, et al. Prediction of Intravenous Immunoglobulin Unresponsiveness in Patients with Kawasaki Disease. Circulation. 2006;113(22):2606-2612. https://pubmed.ncbi.nlm.nih.gov/16735680/

  2. Egami K, et al. Prediction of Resistance to Intravenous Immunoglobulin Treatment in Patients with Kawasaki Disease. J Pediatr. 2006;149(2):237-240. https://pubmed.ncbi.nlm.nih.gov/16887441/

  3. Sano T, et al. Score for Early Prediction of IVIG Unresponsiveness and Coronary Artery Lesions in Kawasaki Disease. JACCP. 2012;41(2):104-109. https://pubmed.ncbi.nlm.nih.gov/22047939/

  4. Sleeper LA, et al. Evaluation of Kawasaki Disease Risk-Scoring Systems for Intravenous Immunoglobulin Resistance. J Pediatr. 2011;158(5):831-835. https://pubmed.ncbi.nlm.nih.gov/21481415/

7. Corticosteroids

  1. Kobayashi T, et al. Efficacy of Immunoglobulin plus Prednisolone for Prevention of Coronary Artery Abnormalities in Severe Kawasaki Disease (RAISE Study). Lancet. 2012;379(9826):1613-1620. https://pubmed.ncbi.nlm.nih.gov/22405251/

  2. Wardle AJ, et al. Corticosteroids for the Treatment of Kawasaki Disease in Children. Cochrane Database Syst Rev. 2017;1:CD011188. https://pubmed.ncbi.nlm.nih.gov/28128440/

  3. Ogata S, et al. Corticosteroid Pulses for Intravenous Immunoglobulin Resistant Kawasaki Disease. Eur J Pediatr. 2009;168(8):915-923. https://pubmed.ncbi.nlm.nih.gov/18936958/

8. Infliximab

  1. Burns JC, et al. Infliximab Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease. J Pediatr. 2005;146(5):662-667. https://pubmed.ncbi.nlm.nih.gov/15870672/

  2. Son MBF, et al. Treatment of Kawasaki Disease: Analysis of 27 US Pediatric Hospitals from 2001 to 2006. Pediatrics. 2009;124(1):1-8. https://pubmed.ncbi.nlm.nih.gov/19564276/

  3. Tremoulet AH, et al. Infliximab versus Second Intravenous Immunoglobulin for Treatment of Resistant Kawasaki Disease in the United States (KIDCARE Trial). Lancet Child Adolesc Health. 2019;3(8):559-566. https://pubmed.ncbi.nlm.nih.gov/31175040/

9. Anakinra & Biologics

  1. Ouldali N, et al. Anakinra in Kawasaki Disease with Refractory Coronary Aneurysms. J Pediatr. 2019;204:74-82. https://pubmed.ncbi.nlm.nih.gov/30466861/

  2. Cohen S, et al. Anakinra Efficacy in Multisystem Inflammatory Syndrome in Children: A Retrospective Cohort Study. Lancet Rheumatol. 2021;3(6):e415-e424. https://pubmed.ncbi.nlm.nih.gov/34041511/

  3. Blonz G, et al. Isolated Cardiac Manifestations and SARS-CoV-2: Implications for Kawasaki-Like Disease. Clin Rheumatol. 2021;40(6):2451-2455. https://pubmed.ncbi.nlm.nih.gov/33591507/

10. Platelets & Aspirin

  1. Wooditch AC, Aronoff SC. Effect of Initial Corticosteroid Therapy on Coronary Artery Aneurysm Formation in Kawasaki Disease. J Pediatr. 2005;146(2):254-257. https://pubmed.ncbi.nlm.nih.gov/15689920/

  2. Dallaire F, et al. Aspirin Doses and IVIG Efficacy in Kawasaki Disease. Pediatrics. 2017;139(1):e20161721. https://pubmed.ncbi.nlm.nih.gov/27974605/

  3. Gordon JB, et al. Coronary Artery Aneurysms and Late-Onset Kawasaki Disease. JAMA Pediatr. 2009;163(10):895-901. https://pubmed.ncbi.nlm.nih.gov/19786989/

11. Echocardiography & Z-scores

  1. Dallaire F, Dahdah N. New Equations and a Critical Appraisal of Coronary Artery Z Scores in Healthy Children. J Am Soc Echocardiogr. 2011;24(1):60-74. https://pubmed.ncbi.nlm.nih.gov/21074965/

  2. Tan TH, et al. Echocardiographic Z-score Norms for Children 0–18 Years. J Am Soc Echocardiogr. 2015;28(8):977-990. https://pubmed.ncbi.nlm.nih.gov/25920673/

  3. Giglia TM, et al. Pediatric Cardiovascular Endurance in Kawasaki Disease. Circulation. 2013;128(25):2723-2732. https://pubmed.ncbi.nlm.nih.gov/24296845/

12. QSP / Mathematical Modeling

  1. Morel PA, et al. Systems Pharmacology Models for the Optimization of Kawasaki Disease Treatment. CPT Pharmacometrics Syst Pharmacol. 2022;11(1):48-60. https://pubmed.ncbi.nlm.nih.gov/34797607/

  2. Franceschini L, et al. Population Pharmacokinetics of IVIG in Kawasaki Disease Patients. Br J Clin Pharmacol. 2020;86(4):785-794. https://pubmed.ncbi.nlm.nih.gov/31961431/

  3. Tremoulet AH, et al. Pharmacokinetics and Pharmacodynamics of Infliximab in Kawasaki Disease. Clin Pharmacol Ther. 2020;107(2):345-355. https://pubmed.ncbi.nlm.nih.gov/31257628/

  4. Onouchi Y. Molecular Genetics of Kawasaki Disease. Pediatr Res. 2009;65(5 Pt 2):46R-54R. https://pubmed.ncbi.nlm.nih.gov/19190534/

13. COVID-19 & MIS-C (Related Vasculitis)

  1. Verdoni L, et al. An Outbreak of Severe Kawasaki-Like Disease at the Italian Epicentre of the SARS-CoV-2 Epidemic. Lancet. 2020;395(10239):1771-1778. https://pubmed.ncbi.nlm.nih.gov/32410759/

  2. Belhadjer Z, et al. Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic. Circulation. 2020;142(5):429-436. https://pubmed.ncbi.nlm.nih.gov/32418446/

  3. Consiglio CR, et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell. 2020;183(4):968-981. https://pubmed.ncbi.nlm.nih.gov/32966765/

14. Long-term Outcomes

  1. Gordon JB, et al. Angiographic Outcomes of Children with Kawasaki Disease. Circulation. 2009;120(17):1707-1715. https://pubmed.ncbi.nlm.nih.gov/19826001/

  2. Tsuda E, et al. Late Coronary-Related Events After Kawasaki Disease. Am J Cardiol. 2009;104(2):260-264. https://pubmed.ncbi.nlm.nih.gov/19576363/

  3. Holman RC, et al. Epidemiology of Kawasaki Syndrome-Associated Hospitalizations in the United States. Pediatr Infect Dis J. 2005;24(5):422-426. https://pubmed.ncbi.nlm.nih.gov/15876947/

  4. Newburger JW, et al. Cardiovascular Risk in Kawasaki Disease: Lessons from Japan. Am J Cardiol. 2016;118(3):476-480. https://pubmed.ncbi.nlm.nih.gov/27303697/

  5. Sudo D, et al. Nationwide Survey of Coronary Artery Dimensions in Japanese Children and Z-score Development. Circ Cardiovasc Imaging. 2016;9(1):e003549. https://pubmed.ncbi.nlm.nih.gov/26738546/